These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

350 related items for PubMed ID: 9684808

  • 1. Effective use of BCH-2763, a new potent injectable direct thrombin inhibitor, in combination with tissue plasminogen activator (tPA) in a rat arterial thrombolysis model.
    Deschênes I, Finkle CD, Winocour PD.
    Thromb Haemost; 1998 Jul; 80(1):186-91. PubMed ID: 9684808
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Hirudin (desirudin) and Hirulog (bivalirudin) in acute ischaemic syndromes and the rationale for the Hirulog/Early Reperfusion Occlusion (HERO-2) Study.
    White HD, Ellis CJ, French JK, Aylward P.
    Aust N Z J Med; 1998 Aug; 28(4):551-4. PubMed ID: 9777138
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-rich thrombus? Effects of recombinant hirudin, heparin, or aspirin.
    Mruk JS, Zoldhelyi P, Webster MW, Heras M, Grill DE, Holmes DR, Fuster V, Chesebro JH.
    Circulation; 1996 Feb 15; 93(4):792-9. PubMed ID: 8641009
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Direct thrombin inhibitors as adjuncts to thrombolytic therapy.
    French JK, White HD.
    Curr Cardiol Rep; 1999 Sep 15; 1(3):184-91. PubMed ID: 10980840
    [Abstract] [Full Text] [Related]

  • 11. Comparison of desulfatohirudin (REVASC) and heparin as adjuncts to thrombolytic therapy with reteplase in a canine model of coronary thrombosis.
    Martin U, Dörge L, Fischer S.
    Br J Pharmacol; 1996 May 15; 118(2):271-6. PubMed ID: 8735626
    [Abstract] [Full Text] [Related]

  • 12. Direct thrombin inhibition and thrombolytic therapy: rationale for the Hirulog and Early Reperfusion/Occlusion (HERO-2) trial.
    White HD.
    Am J Cardiol; 1998 Oct 22; 82(8B):57P-62P. PubMed ID: 9809893
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Hirudin and Hirulog.
    White H.
    Aust N Z J Med; 1993 Dec 22; 23(6):769-70. PubMed ID: 8141724
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Thrombin inhibitors and anti-coagulants on thrombin-induced embolisation in rabbit cranial vasculature.
    Liu JT, Paul W, Emerson M, Cicala C, Page CP.
    Eur J Pharmacol; 1994 Oct 24; 264(2):183-90. PubMed ID: 7851481
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A pilot, early angiographic patency study using a direct thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction.
    Lidón RM, Théroux P, Lespérance J, Adelman B, Bonan R, Duval D, Lévesque J.
    Circulation; 1994 Apr 24; 89(4):1567-72. PubMed ID: 8149522
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.